- Home
- KALA vs FRSX Comparison
KALA vs FRSX Comparison
Compare KALA & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- FRSX
- Stock Information
- Founded
- KALA 2009
- FRSX N/A
- Country
- KALA United States
- FRSX Israel
- Employees
- KALA N/A
- FRSX N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- FRSX Computer Software: Prepackaged Software
- Sector
- KALA Health Care
- FRSX Technology
- Exchange
- KALA Nasdaq
- FRSX Nasdaq
- Market Cap
- KALA 27.7M
- FRSX N/A
- IPO Year
- KALA 2017
- FRSX 2017
- Fundamental
- Price
- KALA $5.11
- FRSX $0.67
- Analyst Decision
- KALA Strong Buy
- FRSX
- Analyst Count
- KALA 2
- FRSX 0
- Target Price
- KALA $16.50
- FRSX N/A
- AVG Volume (30 Days)
- KALA 12.5K
- FRSX 34.2K
- Earning Date
- KALA 11-11-2024
- FRSX 11-20-2024
- Dividend Yield
- KALA N/A
- FRSX N/A
- EPS Growth
- KALA N/A
- FRSX N/A
- EPS
- KALA N/A
- FRSX N/A
- Revenue
- KALA N/A
- FRSX $666,000.00
- Revenue This Year
- KALA N/A
- FRSX N/A
- Revenue Next Year
- KALA N/A
- FRSX N/A
- P/E Ratio
- KALA N/A
- FRSX N/A
- Revenue Growth
- KALA N/A
- FRSX 86.55
- 52 Week Low
- KALA $4.21
- FRSX $0.61
- 52 Week High
- KALA $10.97
- FRSX $2.10
- Technical
- Relative Strength Index (RSI)
- KALA 35.30
- FRSX 43.82
- Support Level
- KALA $5.04
- FRSX $0.61
- Resistance Level
- KALA $5.39
- FRSX $0.69
- Average True Range (ATR)
- KALA 0.23
- FRSX 0.04
- MACD
- KALA 0.00
- FRSX 0.00
- Stochastic Oscillator
- KALA 18.99
- FRSX 52.10
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.